{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=14&q=castration-resistant", "query": { "q": "castration-resistant", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 768, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=15&q=castration-resistant&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=13&q=castration-resistant&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:39:01.750Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Malignancies", "Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "AZD4635", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 313, "start_date": "2016-06-17", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 17, "location_summary": "Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740985" }, { "nct_id": "NCT04854369", "title": "68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Prostatic Neoplasms", "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tulane University", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2023-04-11", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04854369" }, { "nct_id": "NCT04986423", "title": "ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "ZEN003694", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zenith Epigenetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 200, "start_date": "2021-09-08", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 16, "location_summary": "Los Angeles, California • San Francisco, California • Whittier, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Margate", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04986423" }, { "nct_id": "NCT01368003", "title": "STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate" ], "interventions": [ { "name": "STA9090", "type": "DRUG" }, { "name": "STA9090 with Dutasteride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Toni Choueiri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2011-04", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2015-09-01", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01368003" }, { "nct_id": "NCT01934790", "title": "Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2013-12-22", "completion_date": "2017-04-12", "has_results": true, "last_update_posted_date": "2018-03-26", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 3, "location_summary": "New Orleans, Louisiana • Omaha, Nebraska • Syracuse, New York", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01934790" }, { "nct_id": "NCT02204072", "title": "BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "BI 836845", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2014-11-11", "completion_date": "2023-06-01", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 3, "location_summary": "Detroit, Michigan • New York, New York • Portland, Oregon", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02204072" }, { "nct_id": "NCT05730712", "title": "Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Hyaluronidase-zzxf/Pertuzumab/Trastuzumab", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 7, "start_date": "2024-03-08", "completion_date": "2025-04-10", "has_results": true, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05730712" }, { "nct_id": "NCT03822845", "title": "Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostatic Neoplasms", "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "Ga-68 PSMA-HBED-CC PET", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Graham PhD, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2019-03-01", "completion_date": "2021-03-30", "has_results": true, "last_update_posted_date": "2025-04-17", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03822845" }, { "nct_id": "NCT00936975", "title": "Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Metastatic Malignant Neoplasm in the Bone", "Recurrent Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Fluorine F 18 Sodium Fluoride", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2009-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2015-07-16", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00936975" }, { "nct_id": "NCT03110588", "title": "Phase I Trial of PACE for Metastatic Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "PACE with Cabazitaxel (15 mg/m2)", "type": "DRUG" }, { "name": "PACE with Cabazitaxel (20 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2018-05-09", "completion_date": "2019-12-18", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-15T12:39:01.750Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110588" } ] }